Imaxio, which was created partly from a spin-off from the Medical Research Council and Cambridge University in the UK, raises extra funds.
Imaxio, a France-based vaccine and genomics business, raised €2.9m ($3.8m) from Pradeyrol Développement on Wednesday.
Imaxio said the funds would be used for the clinical development of its vaccine-carrying protein platform, designed to improve the efficacy of vaccinations against human and animal diseased.
It added the funds would also be used to also commercialising its vaccine against human leptospirosis, Spirolept, which is already marketed in France.
Imaxio was created by the merger Diagnogene and Avidis, a spin-off from the Medical…
